0001415889-24-004234.txt : 20240216
0001415889-24-004234.hdr.sgml : 20240216
20240216182513
ACCESSION NUMBER: 0001415889-24-004234
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240215
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colgan Erin
CENTRAL INDEX KEY: 0001843563
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 24649991
MAIL ADDRESS:
STREET 1: C/O SENSEI BIOTHERAPEUTCS, INC.
STREET 2: 1405 RESEARCH BLVD., STE. 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 1405 RESEARCH BLVD, SUITE 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
form4-02162024_110205.xml
X0508
4
2024-02-15
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001843563
Colgan Erin
C/O SENSEI BIOTHERAPEUTICS, INC.
1405 RESEARCH BLVD, SUITE 125
ROCKVILLE
MD
20850
false
true
false
false
CHIEF FINANCIAL OFFICER
0
Common Stock
2024-02-15
4
F
0
3627
0.79
D
67462
D
Stock Option (Right to Buy)
0.79
2024-02-15
4
A
0
125000
0
A
2034-02-14
Common Stock
125000
125000
D
Stock Option (Right to Buy)
0.79
2024-02-15
4
A
0
94128
0
A
2034-02-14
Common Stock
94128
94128
D
Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.
/s/ Mark Ballantyne, Attorney-in-Fact
2024-02-16